Sun Life U.S. releases claims report
Analysis based on 6 articles · First reported May 21, 2026 · Last updated May 21, 2026
The release of the report by Sun Life Financial provides critical insights into rising healthcare costs, particularly for high-dollar medical claims and specialty drugs, which can influence investment decisions in the healthcare and insurance sectors. The findings on comorbidities and gene therapies may prompt employers and insurers to adjust coverage strategies, potentially impacting the profitability of companies like Sun Life Financial and pharmaceutical firms.
Sun Life Financial released its annual High-Cost Claims and Injectable Drug Trends report, analyzing over 70,000 medical claims from more than 3,300 self-funded employers. The report identifies secondary conditions, long hospitalizations, and injectable drugs as the primary drivers of claims exceeding $3 million. Common conditions leading to these high costs include orthopedic/musculoskeletal conditions, premature births, and cancer. The report also highlights the increasing frequency of million-dollar claims, a 46% rise from 2022-2026, and the significant cost of gene therapies like Delandistrogene moxeparvovec. Jennifer Colin of Sun Life Financial emphasized the importance of whole-person care to improve health outcomes and manage costs. Sun Life's Health and Risk Solutions, including partnerships with Hinge Health and OptiMed, are designed to address these high-cost factors.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard